To evaluate the efficacy of tamsulosin therapy in reducing ureteral double-J stent morbidity by evaluating USSQ , IPSS , QOL and VAS ( primary objective ) and to evaluate the morbidity and or complication ( s ) associated with indwelling double-J ureteral stent ( s ) and to evaluate the safety of tamsulosin therapy for `` morbidity associated with double-J stents '' by evaluating its tolerability , side effects and adverse events if any ( secondary objective ) as per protocol .